利和兴：10月23日召开董事会会议

Group 1 - The company Lihexing (SZ 301013) held its 15th meeting of the fourth board of directors on October 23, 2025, to discuss various proposals, including the completion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] - For the year 2024, the company's revenue composition is as follows: 74.42% from specialized equipment manufacturing and 25.58% from electronic components manufacturing [1] - As of the report date, Lihexing has a market capitalization of 6.7 billion yuan [1] Group 2 - The Chinese innovative pharmaceutical sector has generated $80 billion in overseas licensing deals this year, indicating a robust market for biopharmaceuticals [1] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising activities, as noted by investor Lu Gang [1]